** Analysts at Jefferies say several factors have the potential to lead to an upside for Integral Diagnostics' IDX.AX FY26 EBITDA estimates
** Brokerage says potential factors include upgrading of Partial to Full MRI Licences, which could drive MRI volumes, as well as lung cancer screening
** Jefferies maintains PT at A$3.60/shr and "buy" rating for stock
** IDX has 16 partial licences that will be upgraded — which should drive MRI volume, thereby increasing co's market share of MRIs by 183bp to 10.3% — brokerage
** All 13 analysts covering stock rate "buy" or higher; their median PT is A$3.10 — LSEG data
** Stock down 10% YTD, as of last close
(Reporting by Shivangi Lahiri in Bengaluru)
((shivangi.lahiri@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.